Pulse Biosciences' First Study In A Surgical Application Of Nanosecond Pulsed Field Ablation Technology To Be Featured In Two Poster Presentations At The American Thyroid Association Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences, Inc. (NASDAQ:PLSE) announced that its Nanosecond Pulsed Field Ablation (nsPFA) technology will be featured in two poster presentations at the American Thyroid Association 2023 Annual Meeting. The first human surgical procedure study on benign thyroid nodules conducted with the nsPFA technology showed complete ablation of the cellular tissue without evidence of thermal necrosis or damage to noncellular structures. The study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules.
September 27, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences' nsPFA technology shows promising results in treating benign thyroid tumors. This could potentially open a new market for the company, positively impacting its stock.
The positive results from the study on nsPFA technology suggest a potential new application for Pulse Biosciences' product. If the technology is adopted for treating benign thyroid tumors, it could lead to increased sales and revenue for the company, which would likely have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100